Susquehanna International Group, LLP Ultragenyx Pharmaceutical Inc. Put Options Transaction History

Susquehanna International Group, LLP

9 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q3 2024 Nov 14, 2024	BUY	$40.21 - $59.36 $3.29 Million - $4.85 Million	81,700 Added 82.53%	180,700 $10 Million
Q2 2024 Aug 15, 2024	SELL	$37.42 - $51.61 $1.36 Million - $1.88 Million	-36,400 Reduced 26.88%	99,000 $4.07 Million
Q1 2024 May 07, 2024	SELL	$43.02 - $53.69 $1.79 Million - $2.23 Million	-41,600 Reduced 23.5%	135,400 $6.32 Million
Q4 2023 Feb 14, 2024	SELL	$31.73 - $49.19 $1.58 Million - $2.45 Million	-49,800 Reduced 21.96%	177,000 $8.46 Million
Q3 2023 Nov 14, 2023	BUY	$34.92 - $46.66 $2.41 Million - $3.22 Million	69,100 Added 43.82%	226,800 $8.09 Million
Q2 2023 Aug 11, 2023	BUY	$37.35 - $52.15 $2.94 Million - $4.1 Million	78,600 Added 99.37%	157,700 $7.27 Million
Q1 2023 May 16, 2023	SELL	$36.99 - $48.71 $1.44 Million - $1.89 Million	-38,800 Reduced 32.91%	79,100 $3.17 Million
Q4 2022 Feb 14, 2023	BUY	$33.72 - $46.33 $890,208 - $1.22 Million	26,400 Added 28.85%	117,900 $5.46 Million
Q3 2022 Nov 14, 2022	BUY	$39.96 - $66.14 $2.53 Million - $4.18 Million	63,200 Added 223.32%	91,500 $3.79 Million

325

85.7M

520K

406K

Ticker RARE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 70,036,896
Market Cap $3.13B
Description
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast...

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

Stay updated on Susquehanna International Group, LLP with notifications on news.